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Abstract
Resistance of Bordetella pertussis, the causative agent of pertussis, to erythromycin is rare. Recently, several Chinese isolates were found to
be erythromycin resistant. This study aimed to investigate the occurrence of pertussis in children suffering persistent cough and the
prevalence of B. pertussis resistance to erythromycin in Xi’an, China. Three hundred and thirteen patients with suspected pertussis admitted
to Xi’an Children’s Hospital from January 2012 through to December 2013 were included and their nasopharyngeal (NP) swabs were taken
for culture and PCRs (targeting IS481 and ptx-Pr). PCR-based sequencing was used to identify the A2047G mutation of B. pertussis 23S
rRNA directly from the NP samples. Sixteen (5.1%) and 168 (53.7%) patients were positive for culture and IS481 PCR. Of the 168 samples
positive for IS481 PCR, 122 (72.6%) and 100 (59.5%) were positive for ptx-Pr and 23S rRNA PCRs, respectively. All culture-positive samples
were also positive for the three PCRs. Fourteen (87.5%) of the 16 B. pertussis isolates were found to be resistant to erythromycin
(MICs > 256 mg/L). All the 14 isolates were conﬁrmed to have a homogeneous A2047G mutation of 23S rRNA. Of the 100 samples
positive for 23S rRNA PCR, 85 (85.0%) were found to have the A2047G mutation by sequencing. Our results indicate that in Xi’an, China,
pertussis remains endemic in young children, and the circulating B. pertussis strains are mostly erythromycin resistant.
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Introduction
Whooping cough or pertussis is an infectious disease of the
human respiratory tract and mainly caused by Bordetella
pertussis. Despite extensive immunizations, the disease has
remained endemic, causing epidemics every 3–5 years. The
highest incidence of pertussis is reported in infants who are
too young to be vaccinated [1–4]. Typical clinical symptoms of
pertussis include paroxysmal cough, whooping and vomiting.
However, young infants, older children, adolescents and adults
often present with atypical symptoms. In these cases, the
diagnosis requires laboratory tests for conﬁrmation [5]. At
present, the laboratory tests available to diagnose pertussis
include bacterial culture, PCR and ELISA serology [5]. For
infants and young children, PCR and/or culture should be
performed on nasopharyngeal (NP) swabs or NP aspirates.
The common target genes used in PCR for the diagnosis of
pertussis are insertion sequence (IS) 481 and pertussis toxin
promoter region (ptx-Pr) [6].
Macrolide antibiotics, especially erythromycin, have been
the antimicrobial drug of choice for treatment and post-expo-
sure prophylaxis of pertussis [7,8]. Almost all B. pertussis
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isolates reported were sensitive for erythromycin all over the
world [9–11], although rare resistant isolates were reported in
the USA and in France [12,13]. Recently, in China, two
B. pertussis strains isolated from healthy schoolchildren in
Shandong province and four strains isolated from sick children
in Shannxi province were found to be erythromycin resistant
[14,15]. So far, the molecular mechanism of B. pertussis
resistance to erythromycin has been associated with an
A2047G mutation in domain V of 23S rRNA [12,15,16].
Susceptibility testing methods are usually performed using
cultured bacterial isolates. However, the culturing of B. per-
tussis from NP samples is time-consuming and accompanied by
low sensitivity [17]. Several days are needed to obtain the
erythromycin susceptibility result of a cultured bacterial
isolate. Furthermore, due to its low sensitivity, only a
proportion of NP samples taken from patients with suspected
pertussis become culture-positive. Because PCR is more
sensitive and rapid than culture, this method is increasingly
used in many countries for the diagnosis of pertussis.
However, the use of PCR instead of culture would make
phenotypic detection of the susceptibility of B. pertussis
isolates to antibiotics impossible [1].
From January 2012 through to December 2013, we carried
out a study aimed at investigating the occurrence of pertussis in
young children with persistent coughing who visited the
Children’s Hospital in Xi’an, the capital city of Shaanxi Province,
China. NP swabs were collected and tested by culture and two
diagnostic PCR assays (targeting IS481 and ptx-Pr). To study the
rate of erythromycin-resistant B. pertussis in Xi’an, China, we
developed a PCR-based sequencing method to detect the
A2047G mutation of 23S rRNA using DNA directly isolated
from the NP swabs that tested positive by the diagnostic PCRs.
Materials and Methods
Immunization and surveillance of pertussis in China
In China, pertussis immunization was introduced in the early
1960s, when three doses of whole-cell vaccine combined with
diphtheria and tetanus toxoids (DTwP) were given at 3, 4 and
5 months of age. Since 1982, a booster dose given at 18–
24 months of age has been added. Since 2006, both DTwP and
acellular pertussis vaccine combined with diphtheria and
tetanus toxoids (DTaP) have been used. From 1983 through
2012, coverage using three doses of DTwP vaccines was
increased from 58% to 99% (median 87%). Since 2008 the
coverage has been >97% [18].
In China, pertussis is a notiﬁed infectious disease and is
clinically diagnosed. Laboratory methods such as culture, PCR
and ELISA are not routinely used. Since the 1990s, reported
annual incidence has been <1 case per 100 000 population
[18]. During the period 2008–2012, the reported number of
cases varied from 1612 to 2517. In 2012, 2183 cases were
reported in this country [18]. According to China CDC, about
90% of reported cases were infants or young children who
suffered from typical pertussis symptoms [19].
Study design and inclusion criteria
This was a prospective study conducted at Xi’an Children’s
Hospital from January 2012 through to December 2013. The
clinical case deﬁnitions recommended by Chinese diagnostic
criteria for pertussis were used for recruiting patients: a cough
lasting more than 2 weeks and/or one of the following:
paroxysms of coughing and/or inspiratory ‘whoop’ and/or
iterative cyanosis and apnoea.
Bacterial culture and diagnostic PCRs
Nasopharyngeal swabs were immediately taken for bacterial
culture and PCR when patients were admitted to the hospital.
The Regen-Lowe culture plates contained charcoal agar
(OXOID) supplemented with cephalexin and 15% deﬁbrinated
sheep blood. The plates were incubated as described previ-
ously and inspected daily for 7 days to determine pertussis-like
colony growth [1]. Suspected colonies were identiﬁed based
on biochemical reactions (positive for catalase and oxidase and
negative for urease), Gram-staining and slide agglutination with
speciﬁc antisera (BD, Sparks, MD, USA) to B. pertussis [1].
DNA used for PCR was extracted from bacterial cultures
and NP swabs by using the QIAamp DNA minikit (Qiagen). To
control for possible contamination of the extraction proce-
dure, a negative control was subjected to the same extraction
procedure with each batch of clinical samples. In this study,
two conventional PCR assays targeting IS481 and ptx-Pr were
used separately. The primers and PCR conditions used were
previously described [20]. Internal ampliﬁcation control (mod-
iﬁed phage lambda) was not used in the PCRs of this present
study. A total of 35 cycles were used for the two PCR assays.
The DNA extracted from the B. pertussis reference strain
(ATCC9797) at a concentration of 100 fg/lL was used as
positive control. All reagents, devoid of added DNA, were
included in the negative control tube in each PCR run. A 5-lL
sample of the PCR products was run in a 2% agarose gel for
detection of speciﬁc PCR product. The sensitivity of PCR
assays was tested by a serial dilution of DNA extracted from
the reference strain of B. pertussis (ATCC9797).
Antimicrobial susceptibility testing
Antimicrobial susceptibilities to erythromycin were performed
by E-Test methods with Bordet-Gengou agar containing 10%
sheep blood as previously reported [21]. Reference strains of
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B. pertussis (ATCC9797) and Staphylococcus aureus
(ATCC25923) were used as controls. All isolated B. pertussis
strains were tested.
PCR-based sequencing of the 23S rRNA gene of B. pertussis
Earlier studies have demonstrated that the resistance of
B. pertussis to erythromycin is caused by a homogeneous
A2047G mutation in domain V of the 23S rRNA gene [16]. We
thus developed a PCR-based sequencing method for directly
detecting the mutation from clinical specimens submitted for
PCR diagnosis of pertussis.
Primers designed were based on the sequence of domain V
of the 23S rRNA gene of Chinese B. pertussis vaccine strain CS
(GenBank accession number CP002695.1). The sequences of
the primers were 1505F: GGCACGAGCGAGCAAGTCTC
and 2118R: TCTGGCGACTCGAGTTCTGC. The PCR reac-
tion mixture (50 lL) contained 25 lL Hotstar Taqmaster mix
(Qiagen), 1 M Betaine (Sigma), 0.5 lM of each primer and
5 lL DNA extract. The DNA fragments were generated by
15 min at 95°C; followed by ﬁve cycles of 30 s at 94°C, 30 s at
68/66/64/62/60°C (decreasing each cycle) and 30 s at 72°C;
followed by 30 cycles of 30 s at 94°C, 30 s at 58°C and 45 s at
72°C. Final extension was with 10 min at 72°C. The PCR
products were resolved by electrophoresis on a 2% TBE
agarose gel and imaging was captured using a Gel Doc
XR+Imager (Bio-Rad). The sensitivity of this PCR was tested
by a serial dilution of DNA extracted from the reference strain
of B. pertussis (ATCC9797). All the PCR-positive products
were sequenced using the forward primer with the Big Dye
Terminator v31 Cycle Sequencing Kit on ABI3730xl (Applied
Biosystems, Carlsbad, CS, USA) from the Life Technology
Corporation (Shanghai, China).
Ethics
This study was approved by the Institutional Review Board of
the Xi’an Center for Disease Control and Prevention, Xi’an,
China.
Results
A total of 313 patients were included in this study (Table 1).
At the time of sampling, 132 (42%) patients were younger than
3 months of age, when the ﬁrst dose of DTwP vaccine is given
according to the Chinese national immunization programme,
and 271 (87%) patients had already received antibiotics, with
cephalosporins (204/313, 65.2%) and/or macrolides (171/313,
54.6%) being mostly used. However, the antibiotic doses taken
were all lower than that recommended for pertussis treatment
[8].
Of 313 NP samples tested by culture, 16 (5.1%) were
positive for B. pertussis (Table 2). All culture-positive patients
had taken antibiotics before the NP sampling. All cul-
ture-positive patients were also positive for the IS481, ptx-Pr
and 23S rRNA PCRs. Of the 313 samples tested by IS481 PCR,
168 (53.7%) were positive. When the 168 NP samples positive
for IS481 PCR were tested by ptx-Pr PCR, 122 (72.6%) were
positive. PCR-positive samples were found during the whole
study period (Fig. 1).
In order to test for possible presence of inhibitory
substances in the NP specimens analysed in this study, DNA
extracted from samples of 24 patients negative for B. pertussis
IS481 PCR was randomly selected and spiked with 1 ng of
B. pertussis DNA. When re-performed by the IS481 PCR, six
samples remained negative, indicating there was inhibition in a
quarter of the negative samples.
Fourteen of the 16 B. pertussis isolates were resistant to
erythromycin. Of the four B. pertussis isolates recovered in
2012, all were found to be resistant to erythromycin (Table 2)
[15]. Of the 12 isolates recovered in 2013, ten were found to
have MIC of erythromycin >256 mg/L; two had MIC of
erythromycin equal to 0.023 mg/L and carried the wild-type
allele at position 2047 in their 23S rRNA. All 14 isolates
resistant to the erythromycin tested were conﬁrmed to have a
TABLE 1. Demographic and clinical characteristics of chil-
dren with suspected pertussis and patients with PCR-con-
ﬁrmed pertussis studied from January 2012 to December
2013
Characteristics
Children with
suspected pertussis
N = 313 (%)
Children with
PCR-conﬁrmed pertussis
N = 122 (%)
Age
Range 6 days to 11 years 1 month to 11 years
95% conﬁdence interval 1 month to 4 years 1 month to 3 years
Median 3 months 2 months
Sex
Male 179 (57.2) 66 (54.1)
Female 134 (42.8) 56 (45.9)
Vaccination statusa
Too young to
be vaccinated
132 (42.2) 57 (46.7)
1 dose 25 (8.0) 8 (6.6)
2 doses 6 (1.9) 3 (2.5)
3 doses 34 (10.8) 8 (6.6)
4 doses 3 (1.0) 1 (0.8)
Unvaccinated 94 (30.0) 38 (31.1)
Unknown 19 (6.1) 7 (5.7)
Days of antibiotic administration
before NP samplingb
1–5 63 (20.1) 17 (13.9)
6–10 95 (30.4) 52 (42.6)
>10 113 (36.1) 46 (37.8)
Unknownc 42 (13.4) 7 (5.7)
aIn China, both the DTwP and diphtheria-tetanus-acellular pertussis (DTaP)
vaccines are given at 3, 4 and 5 months, and a booster dose of DTwP or DTaP is
given at 18–24 months.
bThe antibiotics used include cephalosporins, macrolides, penicillins and/or
Aztreonam (in different formulations).
cNo antibiotic use or no information on antibiotic use.
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homogenous mutation at A2047G of 23S rRNA of their
genomes.
Of the 122 NP swabs positive for both IS481 and ptx-Pr
PCRs, 100 (82.0%) were positive for 23S rRNA PCR and their
PCR products were successfully sequenced. Eighty-ﬁve (85.0%)
were found to have the A to G mutation at position 2047 of
the 23S rRNA gene.
Discussion
Resurgence of pertussis has been reported in many countries,
such as Australia, Canada, the Netherlands, the UK and the
USA [22,23]. However, little is known about occurrence of
pertussis in China [18]. This present study aimed to investigate
the occurrence of pertussis in infants and children suffering
from persistent cough and the prevalence of B. pertussis
resistance to erythromycin in China. Our results conﬁrm that
pertussis remains endemic in infants and children in China.
Furthermore, B. pertussis circulating in this country has
become resistant to erythromycin, with more than 85% of
isolated strains resistant to erythromycin. To our knowledge,
this is the ﬁrst report of both PCR and culture-conﬁrmed
pertussis cases from China during the last 40 years and of
emergence of erythromycin-resistant B. pertussis in China.
In this study, in addition to bacterial culture, two PCR assays
targeting IS481 and ptx-Pr were used to detect B. pertussis
nucleic acids in the clinical samples. The two PCR targets have
been recommended for use in the USA and Europe [24,25]. To
avoid the ‘indeterminate’ result due to the high number of PCR
cycles [24], only 35 cycles were applied for the two diagnostic
PCR assays. Because B. pertussis contains up to 238 copies of
IS481 and only one copy of the pertussis toxin gene [26],
IS481-based PCR is proven to be more sensitive than
ptx-Pr-based PCR. Indeed in our study, in addition to 122
patients who were conﬁrmed as having pertussis by both
PCRs, IS481 PCR detected 46 additional patients. IS481 has
been detected in other Bordetella species; whether these 46
patients were infected by B. pertussis, B. bronchiseptica or
B. holmesii remains to be shown [27].
TABLE 2. Demographic and clinical characteristics of the 16 culture-positive patientsa
Laboratory
code
Date of
sampling Age Gender
Vaccination
status
Coughing
days
Days of macrolide
useb
Mutation
at A2047G
Erythromycin
MIC(mg/L)
12030 28/02/2012 84 days Male No 19 2 G >256
12072 14/05/2012 86 days Female No 15 11 G >256
12152 14/08/2012 2 years Male 4 dosesc 19 Unknownd G >256
12182 20/09/2012 5 months Female No 15 6 G >256
13030 25/04/2013 3 months Male 1 dose 7 1 A 0.023
13038 27/05/2013 4 months Male No 17 0 A 0.023
13046 25/06/2013 2 months Male No 10 2 G >256
13055 05/07/2013 2 months Male No 15 3 G >256
13068 30/07/2013 9 years Female Unknown 15 4 G >256
13091e 26/08/2013 4 months Female 1 dose 16 5 G >256
13092e 26/08/2013 4 months Male 1 dose 16 8 G >256
13114 24/10/2013 5 months Male 2 doses 11 0 G >256
13115 30/10/2013 3 months Male 1 dose 16 12 G >256
13116 31/10/2013 3 months Female No 7 0 G >256
13118 04/11/2013 2 months Male No 13 0 G >256
13159 16/12/2013 7 months Male No 15 2 G >256
aResults from the ﬁrst four patients have been reported previously [15].
bi.e. before the time of sampling.
cThis patient received the booster dose at 20 months of age.
dThis patient had taken some antibiotics, but the details are not known.
eThe two patients are twins.
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FIG. 1. The monthly numbers of NP samples collected and IS481 and ptx-Pr PCR-positive samples during the study period of January 2012 to
December 2013.
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It has been shown that some clinical NP samples can contain
inhibitory substances and can inhibit PCR ampliﬁcation [28]. In
our study, six of 24 samples negative for IS481 PCR were
found to contain some inhibitory substances, suggesting that
the PCR positivity rates observed in this study may be lower
than they should be. It is known that real-time PCR can be
more sensitive than conventional block-based PCR [25].
Unfortunately, the diagnostic PCR assays used in this study
were not real-time and quantitative.
Although a small number of erythromycin-resistant B. per-
tussis strains have been detected by others [12, 14, 15, 29–31],
there have been no reports that erythromycin resistance
amongst B. pertussis isolates is increasing or that its emergence
contributes to the recent increase in the incidence of reported
pertussis across the world. Because culture is reportedly being
used less for diagnosis of pertussis and antimicrobial suscep-
tibility testing is not routinely performed for B. pertussis, it is
possible that resistant B. pertussis strains may be being
overlooked [1].
To overcome the reduction in culturing and avoid missing
infections caused by resistant B. pertussis, we developed a
PCR-based sequencing method for detection of the only
reported mutation causing erythromycin resistance of B. per-
tussis. As a result, this method was successfully used in DNAs
isolated from cultured B. pertussis strains and from clinical NP
samples, with similar resistance rates detected in cultured
B. pertussis strains (87.5%) and 23S rRNA-positive NP samples
(85.0%).
The sequence similarity in 23S rRNA genes between
B. pertussis, B. parapertussis and B. bronchiseptica is > 99%
[32]. As this PCR assay is not able to distinguish between
the three Bordetella species, the assay should be used in
combination with a diagnostic PCR for pertussis (e.g. ptx-Pr
PCR). It should be noted that the sensitivity of this 23S rRNA
PCR was about 10–50 fg (results not shown). Although this
sensitivity was similar to that obtained by the ptx-Pr PCR in
laboratory conditions, only 100 (82.0%) of 122 NP samples
positive for ptx-Pr PCR were positive by the 23S rRNA PCR.
One possible explanation for the difference in sensitivity
between the two PCR methods might be the length of
ampliﬁed PCR products: 615 bp of 23S rRNA PCR vs. 190 bp
of ptx-Pr PCR. It has been reported that the sensitivity of DNA
detection by PCR is inversely related to the size of the
amplicons, as the PCR kinetics favour smaller amplicons [33].
In addition, the possible effect of inhibitors included in clinical
samples on primers and secondary structures of ampliﬁed
products can not be excluded. Indeed, in this study an
inhibition of PCR ampliﬁcation was observed in a quarter of
the negative samples tested. Further study is needed to clarify
the high inhibition rate.
In China, macrolide antibiotics are generally considered to be
the ﬁrst-choice agents for the treatment of bacterial infections
such as Mycoplasma pneumonia. It is known that M. pneumonia
can cause prolonged cough. The reported resistance rates of
M. pneumonia to macrolides were very high, ranging from 83%
to 95% [34,35]. Azithromycin is the most commonly used
antimicrobial agent in hospitals in China [36]. Our study is in line
with these reports in China, with 87% of patients having taken
antibiotics before the sampling, and cephalosporins and mac-
rolides being the most commonly used antibiotics in this
country. In this present study, the percentages of cephalospo-
rins and macrolides used in the patients were 65.2% and 54.6%,
respectively. Although the erythromycin resistance rate was
high in strains of B. pertussis observed in this study, all samples
tested were obtained only from Xi’an, the capital city of Shannxi
province and its surrounding areas. Recently two B. pertussis
isolates obtained in Shandong province, China, were reported
to be resistant to erythromycin [14]. A multicentre study
should be conducted to estimate the prevalence of erythro-
mycin resistance of B. pertussis in China.
The emergence of erythromycin-resistant B. pertussis
strains in Xi’an, China, is alarming. In countries such as China,
antimicrobial susceptibility testing should be carried out for
recovered B. pertussis. In addition, PCR-based sequencing for
rapid detection of possible antimicrobial resistance should be
considered in clinical microbiology laboratories of hospitals,
where the pertussis diagnosis is usually performed.
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